Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 5Hepatitis B, Chronic 3Hepatitis B 3Lymphoma 2Virus Diseases 1Recurrence 1Paraparesis, Tropical Spastic 1Neuritis 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Infections 1HTLV-I Infections 1Fibrosis 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3Oncolytic Virotherapy 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Bevacizumab 2valrubicin 1thymoglobulin 1ledipasvir, sofosbuvir drug combination 1hepatitis C immune globulin, human 1halofantrine 1VP-102 1Therapies, Investigational 1Tenofovir 1Rituximab 1Radiotherapy, Intensity-Modulated 1Papillomavirus Vaccines 1Nimorazole 1Mitomycin 1Lamivudine 1Kidney Transplantation 1Ipilimumab 1Interferons 1Influenza Vaccines 1Immunoglobulin G 1Imiquimod 1Gemcitabine 1Gels 1Fluorescent Antibody Technique 1Drug Therapy 1Cyclophosphamide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Virus Diseases × Tenofovir × Clear all
NCT01528865 2016-03-11

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

University of Michigan Rogel Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡